Biotech Blog Archives: May 2004
next page ·
28 May 2004
The Drug Research War
The Drug Research War
“Mention the term ‘outsourcing,’ and drug development probably doesn’t leap to mind. But this market, which is the heart of pharmaceutical and biotech companies, is growing at a yearly clip of 15% to 20%. Right now the lion’s share of the work has gone to U.S. companies that focus on drug research [...]
continue reading... » 0 Comments
28 May 2004
Biotechs struggle as IPOs find cool reception
Biotechs struggle as IPOs find cool reception
“Five initial public offerings had trading debuts Thursday, bringing mixed results and a message that biotech certainly isn’t what the doctor ordered for the IPO market. “
continue reading... » 0 Comments
25 May 2004
The Health-Care Catastrophe That Won’t Happen
The Health-Care Catastrophe That Won’t Happen
Why biotech gains will rein in medical costs. The lesson of info tech
continue reading... » 0 Comments
23 May 2004
Will U.S. try to circumvent drug firms patent?
Will U.S. try to circumvent drug firms patent?
:
The furor over Abbott Laboratories’ 400 percent price increase last December of the AIDS drug Norvir has resulted in an unprecedented meeting at the National Institutes of Health to consider circumventing the drug giant’s patent.
continue reading... » 0 Comments
23 May 2004
Another gene genie out of the bottle
Another gene genie out of the bottle
The European Commission has lifted a five-year moratorium on genetically modified produce, by allowing the sale in Europe of one type of modified corn. But the battle by producers of such crops to win governments� and consumers� acceptance is far from over
continue reading... » 0 Comments
18 May 2004
Could patients glean stock tips?: Drug trial participants may be insider trading.
Could patients glean stock tips?: Drug trial participants may be insider trading.
“Patients in clinical trials might be using information about the drug they are taking to trade illegally in pharmaceutical stocks, warns a group of doctors and bioethicists. But they have no idea how prevalent the problem might be.”
